Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts Costain at 'buy'

(Sharecast News) - Berenberg initiated coverage of construction and engineering group Costain on Friday with a 'buy' rating and 140p price target. It said the company has overcome its recent challenges, as it improves both its profitability and its free cash generation, and it has strengthened its balance sheet, to the extent that in 2024 it was able to buy back shares for the first time in at least the past 10 years.

It pointed to a pipeline of revenue opportunities. Berenberg said there are significant infrastructure spending commitments in the coming years that it expects to benefit Costain.

"That it ended FY 2024 with a forward work position of £5.4bn, £1.5bn higher than the previous year, suggests the company is capitalising on these opportunities," it said.

"A strong order book not only underpins future revenue but should also enable greater discipline in contract selection and help Costain to pursue only those contracts with acceptable terms."

With this in mind, the bank said its base case is for group revenue to be broadly flat in the coming years, with growth in the Natural Resources division offsetting lower revenue in the Transportation division.

Berenberg also highlighted improving margins and reduced exceptionals.

"Earnings growth will, in our view, be driven by improving margins and fewer exceptionals," it said. "We expect margin growth to be driven by a combination of more higher-margin digital and consulting work, and the ending of older, lower-margin contracts."

It said improved controls were implemented in 2022 and should limit exceptionals.

It pointed out that management expects to achieve its target EBIT margin run-rate of 3.5% during FY 2024 and is targeting 4.5% during FY 2025 and more than 5.0% beyond that.

"These margins are not included in our base case, but we expect a circa 30% incremental benefit to EBIT if they are achieved."

Berenberg also cited the company's balance sheet strength, cash generation and the prospect of further returns.

"Costain's improving free cash flow profile will, in our view, enable it to grow its net cash balance, give the business optionality on further investment, and allow for further shareholder returns," it said.

"We believe Costain should make balance sheet strength an absolute priority, but we nonetheless expect its strong free cash generation to allow for further shareholder returns."

Finally, the bank said the stock's valuation is "undoubtedly cheap", trading at 7.3x FY 2025 price-to-earnings, 1.8x EBITDA and 2.4x EBIT, with an 11.4% free cash flow yield.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.